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Abstract
Background: Symptomatic hypogammaglobulinemia in infancy and childhood (SHIC), may be an
early manifestation of a primary immunodeficiency or a maturational delay in the normal
production of immunoglobulins (Ig). We aimed to evaluate the natural course of SHIC and
correlate in vitro lymphoproliferative and secretory responses with recovery of immunoglobulin
values and clinical resolution.
Methods: Children, older than 1 year of age, referred to our specialist clinic because of recurrent
infections and serum immunoglobulin (Ig) levels 2 SD below the mean for age, were followed for a
period of 8 years. Patient with any known familial, clinical or laboratory evidence of cellular
immunodeficiency or other immunodeficiency syndromes were excluded from this cohort.
Evaluation at 6- to 12-months intervals continued up to 1 year after resolution of symptoms. In a
subgroup of patients, in vitro lymphocyte proliferation and Ig secretion in response to mitogens
was performed.
Results: 32 children, 24 (75%) males, 8 (25%) females, mean age 3.4 years fulfilled the inclusion
criteria. Clinical presentation: ENT infections 69%, respiratory 81%, diarrhea 12.5%. During follow-
up, 17 (53%) normalized serum Ig levels and were diagnosed as transient hypogammaglobulinemia
of infancy (THGI). THGI patients did not differ clinically or demographically from non-transient
patients, both having a benign clinical outcome. In vitro Ig secretory responses, were lower in
hypogammaglobulinemic, compared to normal children and did not normalize concomitantly with
serum Ig's in THGI patients.
Conclusions: The majority of children with SHIC in the first decade of life have THGI. Resolution
of symptoms as well as normalization of Ig values may be delayed, but overall the clinical outcome
is good and the clinical course benign.
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Background
Pediatric patients with "recurrent infections" within our
area are referred to the pediatric immunology clinic in the
Kaplan Medical Center. Few fulfill the clinical criteria of
the immune deficiency "red flags", Table 1, and only in a
small minority, quantitative or qualitative defects in
immunological function are documented. As expected,
most such defects, involve the humoral immune system,
the most common of the primary immune deficiencies
[1,2]. Classically, the clinical presentation, includes a neo-
natal "grace" period, during which the baby is protected
from infection by the presence of passively acquired
maternal antibodies. As the level of these antibodies
decline, the babies present at the end of the first year of
life or the beginning of the second with recurrent respira-
tory, ENT and GI infections. The pathogens involved are
mostly the "usual" bacteria, Streptococcus pneumonia, Hae-
mophilus influenza and Staphilococcus aureus, but the infec-
tions may be of unusual severity, persistence, or
frequency.
In the last 10 years, tremendous advances in the fields of
molecular medicine and genetics, have made possible the
definitive diagnosis of most combined immunodeficiency
patients, agammaglobulinemia patients and clinical syn-
dromes associated immunodeficiency patients, on the
basis of a recognized genetic aberration leading to a pro-
tein product dysfunction [3,4]. Nevertheless, the diagno-
sis of some of the most common forms of primary
immune deficiency, IgA deficiency [5], common variable
immunodeficiency [6] and transient hypogammaglob-
ulinemia of infancy (THGI), are still based on clinical cri-
teria and the exclusion of other specific diagnoses [7,8].
THGI is thought to be caused by a poorly understood mat-
uration delay in the normal production of Ig, extending
the physiologic hypogammaglobulinemia of the new
born beyond the first year of life [1,9]. Currently, there are
no diagnostic tests that differentiate, on initial presenta-
tion of a young child with recurrent infections and low Ig
levels, those that will spontaneously correct on follow-up
from those where a primary and permanent immune defi-
ciency will develop, except for B cell numbers below 2%,
which point towards X-linked agammaglobulinemia
(XLA)[10].
In this study we aimed to evaluate the natural course of
disease in symptomatic hypogammaglobulinemia of
infancy and correlate in vitro lymphoproliferative and
secretory responses to mitogens in this population with
recovery of immunoglobulin values and clinical
resolution.
Methods
Patients
Children more than 1 year of age, with recurrent infec-
tions, defined as more than three episodes of acute otitis
media and/or more than one episode of acute sinusitis
and/or more than one episode of pneumonia or the pres-
ence of a severe deep seated infection (meningitis, septi-
cemia, etc.) within the last 6 months, or fulfillment of one
of the "red flags" of immunodeficiency, see Table 1, and
hypogammaglobulinemia, defined as serum Ig values 2
SD below the age defined norms on two or more measure-
ments [11], have been prospectively recruited from a
cohort of children referred to our clinic because of recur-
rent or severe infections. Patients were seen at presenta-
tion and reevaluated periodically at 6 to 12 month
intervals, up to 1 year after resolution of symptoms.
All procedures were performed according to accepted eth-
ical standards of the Institutional Review Board of Kaplan
Medical Center. The parents of all the children were
informed accordingly and gave their permission for par-
ticipating in the study and blood sampling.
Ig assessment
Total serum Ig levels were measured by nephelometry
(Beckman Immunochemistry Systems, IgM, IgG and IGA
test, Beckman Instruments, Galway, Ireland) and serum
IgG subclasses have been assayed with an
immunodiffusion commercial kit (Human IgG Subclasses
single dilution BINARID, Birgminham, UK). Specific anti-
body production was not evaluated.
In vitro cell proliferation and Ig secretion
Peripheral blood mononuclear cells (PBMC) were iso-
lated from heparinized venous blood of patients and age-
matched donors (children hospitalized or attending the
outpatient clinic for unrelated conditions) on ficoll iso-
paque gradients (Sigma, St. Louis, MO, USA). Patient and
normal donor cells were cultured in microtiter plates with
culture medium: RPMI medium supplemented with 10%
FCS (Bio-Lab, Jerusalem, Israel), 10 mM Hepes buffer,
100 U/ml penicilin 100 µg/ml streptomycin, 2 mM L-
glutamine, and 100 µg/ml kanamycine (Sigma Israel),
and were grown at 37°C with 7.5% CO2 in air. 5 × 105
cells were stimulated for four days with 0.01% w/v SAC
(Calbiochem, La Jolla, CA, USA), 2.5 µg/ml PWM, 20 µg/
ml E. coli: O55:B5 LPS or with 20 µg/ml PHA (Sigma, St.
Louis, MO, USA). The cells were then pulsed with 1 µCi/
well of [3H]-Thymidine (Nuclear Research Center, Negev,
Israel) and incorporated radioactivity was measured by a
β scintillation counter. Proliferation was expressed as
stimulation index (SI).
In parallel, cell culture supernatant aliquots were har-
vested and Ig isotype concentrations were measured in theBMC Family Practice 2004, 5:23 http://www.biomedcentral.com/1471-2296/5/23
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culture supernatants, by a solid-phase immunoassay, in
Nunc- Immunoplate Maxisorp 96 wells (Nunc, Den-
mark). The plates were coated with goat anti-human IgM,
IgG or IgA antibodies (Jackson Immunoresearch Labora-
tories, West Grove PA, USA). Biotinilated goat anti-
human IgM, IgG or IgA (Jackson, West Grove, PA, USA)
and streptavidin-alkaline phosphatase (Amersham, Buck-
inghamshire, England) were used for measurement of
IgM, IgG and IgA respectively. Resulting yellow dye inten-
sity was read by an ELISA reader (Microplate Auto-Reader
Bio-Tek Instruments, VT, USA). Dye units were converted
to immunoglobulin concentrations by extrapolation from
standard curves determined by using purified myeloma
proteins of known concentration in every assay.
Statistical analysis
We used non-parametric tests to compare the means
(Kruskal Wallis test for k independent samples) and a
standard analysis of variance to compare between groups.
Logistic regression analysis was used for comparison of
distribution of dichotomous values between the groups.
Analysis was performed using SPSS for windows ver 9.0.
Results
32 patients were included in the study, 24 males (75%)
and 8 females (25%) with a mean age at diagnosis of 3.4
years (range 1.2 – 7.0). Clinical presentations included
severe and recurrent Ear-Nose-Throat (ENT) infections –
22 patients (69%), pneumonia, bronchopneumonia or
severe, recurrent upper respiratory infections – 26 patients
(81%), diarrhea – 4 (12.5%) and atopy related com-
plaints – 20 patients (63%). A positive family history of
Table 1: Clinical "Red Flags" for Immunodeficiency
1 Eight or more new ear infections within 1 year
2 Two or more serious sinus infections in 1 year
3 Two or more months on antibiotics with no effect
4 Two or more pneumonias within one year
5 Failure of an infant to gain weight or grow well
6 Recurrent, deep skin or organ abscesses
7 Persistent thrush in the mouth or elsewhere on the skin, after age 1
8 Need for intravenous antibiotics to clear infection
9 One or more deep-seated infections such as sepsis, meningitis or cellulitis
10 A family history of primary immune deficiency or early infant death from infection, recurrent infection, malignancy, or autoimmune disease
Adapted from: Primary Immunodeficiency Diseases: A molecular and genetic approach New York, Oxford University Press, 1999.
Table 2: Clinical and Demographic Data of Patient Cohort
THGI Non Transient p
Demographics No of Patients 17 (53%) 15 (47%) > 0.05
Males 15 (88%) 9 (60%) > 0.05
Females 2 [30] 6 [31] > 0.05
Average age at Diagnosis 3.6 years 3.1 years > 0.05
Clinical Data ENT 10 (59%) 12 (80%) > 0.05
Respiratory 15 (88%) 11 (73%) > 0.05
GI 2 [32] 2 [33] > 0.05
Atopy 11 (65%) 9 (60%) > 0.05
Family History 4 (24%) 3 (20%) > 0.05
Diagnosis IgAD 9 (53%) 7 (48%) > 0.05
IgGD 12 (71%) 10 (68%) > 0.05
IgMD 2 [34] 3 (20%) > 0.05
Treatment Antibiotics 4 (24%) 8 (53%) > 0.05
IVIg 2 [35] 1 [36] > 0.05
Outcome No Infections 14 (83%) 13 (87%) > 0.05
Follow-up (years) Age at last follow-up 7.1 5.5 > 0.05
Length of follow-up 3.5 2.5 > 0.05
THGI – Transient Hypogammglobulinemia of Childhood
Non Transient – Hypogammaglobulinemic patients who did not correct during follow-up
IgAD – IgA 2SD bellow age specific norms
IgGD – One or more IgG isotype 2SD bellow age specific norms
IgMD – IgM 2SD bellow age specific normsBMC Family Practice 2004, 5:23 http://www.biomedcentral.com/1471-2296/5/23
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recurrent, unusual or severe infections was obtained in 7
patients (22%). Demographical and clinical data of
patient cohort is summarized in Table 2.
Out of the initial 32 patients, 17 (53%) spontaneously
corrected their Ig abnormalities. This group included 15
boys (88%) and 2 girls[12], mostly in the second or third
year of life, average age at diagnosis being 3.6 years (range
1.3–9). The two groups, those with essentially transient
hypogammaglobulinemia – THGI and those who did not
correct their Ig values during the follow up period did not
differ significantly at diagnosis, see Table 2.
All defects were partial, no patient in this group, showing
a complete absence of a given Ig isotype. The clinical
course was benign, only 9.4% (3/32) patients requiring
IVIg (2 in the THGI group, 1 in the non corrected group).
38% (12/32) of patients received prolonged antibiotic
prophylaxis (4/17 in the THGI and 8/15 in the non cor-
rected group, p = 0.09) and resolution of clinical symp-
toms occurred in 84% of patients (14/17 in the THGI and
13/15 in the non corrected group). All calculated p values,
non significant for comparison between the 2 groups.
Comparative analysis of serum Ig isotype levels at diagno-
sis showed no significant difference, between the transient
and non-transient group.
In vitro lymphocyte proliferation and Ig secretion were
measured in 9 patients (5 patients with THGI and 4 with
non-corrected IGD) on one or more occasions. Lym-
phocytes proliferative responses to SAC, PWM and LPS
showed no differences between the groups and no signif-
icant differences from childhood norms. The proliferative
response to PHA was significantly increased (p < 0.005)
after the correction of Ig abnormalities, overshooting nor-
mal controls (Fig 1).
Quantification of the in-vitro immunoglobulin secretion
in response to the various mitogens showed significant
isotype and mitogen dependent variation. The IgM secre-
tory response to PWM and LPS, was low in hypogamma-
globulinemic patients. After normalization of serum Ig
values, the IgM response to LPS stimulation increased, see
table 3. However, the improved response to LPS was still
lower than age matched controls (p < 0.05).
For both IgG and IgA, the response in normal children
was significantly better than in either group of patients.
The IgA secretion index to all 3 stimulatory mitogens was
minimal in hypogammaglobulinemic patients, even after
serum Ig correction and differed significantly from age
matched controls (p < 0.005 for SAC, p < 0.05 for PWM,
p < 0.05 for LPS), table 3. The IgG secretion index in
hypogammaglobulinemic patients was slightly better to
LPS than to other mitogens (non significant) and differed
significantly from age matched controls (p < 0.05 for SAC,
p < 0.005 for PWM, p < 0.05 for LPS). No difference was
observed on either test between THGI and non corrected
patients on initial presentation.
Lymphocyte proliferation after in-vitro mitogenic stimuli in Pediatric Hypogammaglobulinemia Figure 1
Lymphocyte proliferation after in-vitro mitogenic stimuli in Pediatric Hypogammaglobulinemia. SAC – Staph. 
Aureus Cowan. PWM – Pokeweed Mitogen PHA – Phytohemmaglutinin LPS – Lipopolysacharide Values are given as Stimula-
tion Index (SI) mean ± 95% CI, ** p < 0.005
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Discussion
Young patients with recurrent infections represent a sizea-
ble portion of the daily practice of all primary care pedia-
tricians and family physicians, with parents clamoring for
a solution with the accumulation of lost daycare or school
days. The physician is faced with the dilemma when
parental assurance will suffice, rather than initiation of a
costly immunological investigation. Often, the presenting
clinical signs and symptoms are insufficient for an edu-
cated diagnosis, as well as Ig levels in infants below the
age of one year. The present investigation was initiated in
order to try to contribute additional understanding how
to differentiate between cases of primary immune defi-
ciency and those who are not.
We prospectively studied the outcome of SHIC in 32
patients during a period of 8 years, mean follow up of 3.2
years. During this time more than half corrected their Ig
abnormalities. The mean follow up of the non-corrected
IGD group is slightly shorter (though not statistically sig-
nificant) than that of the THGI group (2.5 years and 3.5
years respectively) which leads us to speculate that some
patients in the "non-transient" group may eventually cor-
rect. This is consistent with previously published reports
from Dalal et al. who, after a follow up of 10 years, found
that 70% of patients had complete resolution of their Ig
abnormalities [13].
Interestingly, the majority of our patients were males
(75%), and a higher proportion of males corrected their
serum Ig (15/24 males and 2/8 females). This finding of
male preponderance is not uniquely ours. In the reports of
Dalal et al. [14], 24/35 (69%) and Walker et al. [15] 29/
39 (74%) of patients included in the study were male. We
found no readily available explanation for this
phenomenon.
It is impossible to estimate the prevalence of THGI in
Israel, from our data, since our patients are part of a biased
referral clinic population. Still, our impression is that this
diagnosis is perhaps the most common of the Ig deficien-
cies in childhood, an impression supported by a number
of publications from different groups [16,17].
In the paragraph on THGI in the most recent Scientific
Group Report on the subject [1], the age cutoff of recovery
of normal Ig synthesis capability "may be delayed for as
long as 36 months". In contrast, in our series of patients,
normalization to age adjusted Ig levels, has occurred in
some cases at 8 or 9 years of age. These results are consist-
ent with Dalal et al [18], who also describe resolution of
THGI over the first decade of life. A more recently
published series [19], 7/40 [20] of patients with THGI,
still had low levels of antibodies at age 5 years. More over,
the benign course of the group of patients who did not
correct their Ig values during the course of our follow up,
may indicate that a significant portion of these patients
may actually still belong to the THGI group and will cor-
rect on subsequent follow up. These combined observa-
tions may induce a change in the classical definition and
diagnostic criteria for THGI [21].
The majority of patients (84%) resolved their tendency for
recurrent infections irrespective of their Ig values. Only a
minority of patients required any medical intervention,
38% received antibiotic prophylaxis and only 9% intrave-
nous Ig replacement therapy. We observed no difference
in the clinical presentation or follow up of the transient
group as compared to the non corrected IGD patients and
resolution of serum Ig abnormality did not cause a
complete clinical remission in all patients. This may be
due to a residual inability to mount an adequate antibody
response to specific antigen challenge, data that has not
been evaluated in our series. The impaired IgG and IgA in
vitro secretory responses, seen in hypogammaglobuline-
Table 3: Immunoglobulin Secretion from B-cells after in-vitro mitogenic stimuli in Pediatric Hypogammaglobulinemia
SAC PWM LPS
IgM IgG IgA IgM IgG IgA IgM IgG IgA
Hypogamma 1.6 1.2 * 1.1 ** 1.1 * 1.4 * 1.3 * 1.3 * 2.0 * 1.1 *
(0.6–2.6) (0.9–1.5) (1.0–1.2) (0.9–1.3) (0.9–1.9) (1.0–1.6) (1.1–1.5) (1.1–2.9) (1.0–1.2)
Corrected 2.8 1.0 * 1.3 * 1.0 * 1.1 ** 1.3 * 2.2 * 1.5 * 1.2 *
(1.7–3.9) (0.9–1.1) (1.0–1.6) (0.9–1.1) (1.0–1.2) (1.1–1.5) (1.4–3.0) (1.2–1.8) (1.0–1.4)
Normal 3.0 2.5 2.3 2.6 3.0 2.2 4.4 5.0 3.4
(2.5–3.5) (1.9–3.1) (1.8–2.8) (2.2–3.0) (2.4–3.6) (1.7–2.7) (3.9–4.9) (3.5–6.5) (3.0–3.8)
SAC – Staph. Aureus Cowan. PWM – Pokeweed Mitogen
LPS – Lipopolysacharide
Values are given as Secretion Index Mean and (95% confidence interval)
** p < 0.005 compared to normal controls
* p < 0.05 compared to normal controlsBMC Family Practice 2004, 5:23 http://www.biomedcentral.com/1471-2296/5/23
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mic patients, even after serum Ig normalization, may be
an expression of such an inability, which warrants further
investigation.
Atopy was a prominent associated complaint in 21/37
(57%) of our patients. Especially so in comparison with
the prevalence of asthma in this age group in Israel – 7%
[22,23] and the estimated prevalence of other atopy asso-
ciated diseases, about 20%. This finding was inconsist-
ently reported by other investigators [24,25].
Though no clinical evidence of T-cell functional impair-
ment was observed in our patients (no opportunistic, fun-
gal or chronic viral infections), previous reports [26-28]
suggest that the apparent B cell defect may be secondary
to a T cell dysfunction such as T cell cytokine disregula-
tion. We have shown that cellular and humoral responses
to mitogenic stimuli tend to be lower in SHIC patients as
compared to normal children but do not differentiate
THGI from patients with more persistent hypogamma-
globulinemia. Lymphocyte proliferation in response to
PHA is significantly increased after Ig correction in THGI,
overshooting normal controls. The molecular basis of this
observation is unclear. In vitro IgM secretion is less
impaired than other isotypes and in THGI a definite
improvement of IgM secretion with SAC and LPS stimula-
tion occurs concomitantly with correction of serum Ig.
The IgG and IgA secretion in response to mitogenic stim-
uli is severely impaired and does not normalize concomi-
tantly with serum Ig, indicating a possible impairment in
the isotype switching mechanism. This observation is sup-
ported by the previous long term follow-up reported by
Dalal [29] where specific IgG antibody responses to
polysaccharide antigen were reduced even after the
resolution of the serum Ig deficiency in a large subgroup
of patients with apparently resolved THGI.
Conclusions
THGI is a relatively common cause of symptomatic
hypogammaglubulinemia in infancy in our area. Most
children will spontaneously correct their Ig abnormalities
during the first decade of life. Though tests of cellular or
humoral stimulation index, are not as yet capable of dif-
ferentiating the transient from the non-transient patients
upon their presentation, significant isotype and mitogen
specific variability is evident. The relative preservation of
the in vitro IgM secretory response and the lack of IgA/IgG
response in patients with hypogammaglobulinemia,
argues for a delay in isotype switching as the molecular
basis underlying the clinical entity of transient hypogam-
maglobulinemia of infancy.
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